# nature portfolio

Corresponding author(s):	Yann Humeau
Last updated by author(s):	Sep 27, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
C -	トつ	tı	ct	ics
	п		<b>&gt;</b> 1	11 >

n/a	Confirmed				
	$\square$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	🔘 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statist	tical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.			
	A descript	ion of all covariates tested			
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Polic	cy information a	about <u>availability of computer code</u>			
Da	ata collection	The scripts that have been used for ripple analysis can be found at the following address: https://figshare.com/account/home#/projects/179595.			
Da	ata analysis	For data analysis, statistical comparisons and figure production, the sigmaplot 12 suite from systatsoftware was used.			
Form	For manuscripts utilizing system algorithms or software that are control to the research but not vet described in published literature, software must be made available to adjust and				

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All single data can be found at the following address: https://figshare.com/account/home#/projects/179595

## Research involving human participants, their data, or biological material

Policy information a and sexual orientation		with human participants or human data. See also policy information about sex, gender (identity/presentation), thnicity and racism.			
Reporting on sex a	and gender	N/A			
Reporting on race other socially release groupings		N/A			
Population charac	teristics	N/A			
Recruitment		N/A			
Ethics oversight		N/A			
Note that full informat	ion on the appro	oval of the study protocol must also be provided in the manuscript.			
Field-spe	cific re	porting			
· · · · · · · · · · · · · · · · · · ·		the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
∠ Life sciences	В	ehavioural & social sciences			
For a reference copy of th	ne document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scien	ces stu	ıdy design			
All studies must disc	close on these	points even when the disclosure is negative.			
'	The specific sample size for each analysis is summarised in the figure legends, main text and methods. Throughout the manuscript, n refers to the number of independent experiments or to the number of animals as indicated for each analysis (see legends). For behavioral experiments, a minimal sample size of 5 animais was chosen to ensure the findings were reproducible, while minimising animal numbers.				
	injections were in the same side	n vivo pharmacological experiments, animals were excluded if histological controls indicated off-target implantations, or if bilateral cions were not completed. For pharmacological effects on ripples during sleep, experiments were considered if a good injection was done a same side as the used electrophysiological channel. A few excluded experiment are listed in the "source data file" available online ://figshare.com/account/home#/projects/179595.			
'	Key experiments (pre-rest or pre-learning AM PAR X-linking using two different strategies) were performed on at least 3 different cohorts of Wf or KI mice, and gave similar results. In vivo pharmacological controls were contributed by injection failures and eventual off targets, but always included significant groups of yet published controls.				
Randomization	All cohorts were randomized, including control and X-linking conditions, and main results were repeated several times.				
Blinding	Ali analyses were done blind to the presence or absence of the AMPAR X-linking (either animal genotype or pharmacological treatment).				
We require informatio	n from authors a	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & exp					
n/a Involved in the study  Antibodies		n/a   Involved in the study   ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
Palaeontology and archaeology					
Animals and	Animals and other organisms				
Clinical data					
Dual use research of concern					
Plants					

### **Antibodies**

Antibodies used

Monoclonal whole IgGI-K and Fab fragments recognising the extracellular domain of GluA2 (clones 15Fl and 14B11, gifts from E. Gouaux), were prepared using the purified GluA2 receptor in detergent solution as the antigen.

Validation

Validation of used antibodies was done in Penn et al., 2017. (10.1038/nature23658)

## Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals

Experiments in this manuscript were conducted on 6 to 12 weeks old male mice belonging to two strains: C57BL6/J wild type and C57BL6/J transgenic AP-GluA2 knock-In (KI, maintained on a C57BL6/J background) strains. Mice were kept on a 12-hour light/dark cycle and provided with ad libitum food and water, except for food restriction associated with behavioural testing (see below). Mice were housed with 3-5 littermates except when demanded by the protocol.

Wild animals

No wild animais were used in this study.

Reporting on sex

Only male mice were used.

Field-collected samples

No field collected animais were used in this study.

Ethics oversight

All procedures were validated by the ethical committee of animal experimental of Bordeaux Universities and the French ministry of Agriculture (CE50; Animal Facility PIV-EXP, APAFIS#18507-201901118522837; Animal Facility A1, APAFIS#4552 2016031019009163; Animal Facilities Neurocentre Magendie and PIV-EXPE, APAFIS#13515- 2018021314415739).

Note that full information on the approval of the study protocol must also be provided in the manuscript.